Butylphthalide Injection

Categories:Qijian News
Author:QIjian
Origin:QIjian
Time of issue:2021-07-30
Views:0

(Summary description)We applied for registration of product Butylphthalide Injection and on July 15,2021 received the notification from CFDA(Acceptance number: CXHL2101298国), "Butylphthalide Injection" Class II New Drugs enters the Clinical Phase.





[Top]

Butylphthalide Injection

Categories:Qijian News
Author:QIjian
Origin:QIjian
Time of issue:2021-07-30
Views:0

Information

We applied for registration of product Butylphthalide Injection and on July 15,2021 received the notification from CFDA(Acceptance number: CXHL2101298国), "Butylphthalide Injection" Class II New Drugs enters the Clinical Phase.

Keyword:

Scan the QR code to read on your phone

Previous: Qijian was invited to participate in "China Service Trade Fair 2021”

Next: Annual examination of drug production license passed

Previous: Qijian was invited to participate in "China Service Trade Fair 2021”

Next: Annual examination of drug production license passed

Previous : Qijian was invited to participate in "China Service Trade Fair 2021”

Next : Annual examination of drug production license passed

Previous : Qijian was invited to participate in "China Service Trade Fair 2021”

Next : Annual examination of drug production license passed

Butylphthalide Injection

Butylphthalide Injection

Related News

Welcome leaders of Jilin Provincial Department of Commerce to Qijian Bio-Pharmaceutical for investigation

In 2024，Jilin Qijian Bio-Pharmaceutical Co., Ltd will take part in the following worldwide professional exhibitions, welcome to visit us

API (Butylphthalein) R&D Site, Production Site Verification and GMP Compliance Inspection of Jilin Qijian Bio-Pharmaceutical Co.,Ltd successfully passed.

CPHI Worldwide will be held in Barcelona, Spain on October 24-26, 2023.Jilin Qijian Bio-Pharmaceutical Co.,Ltd will attend the exhibition, Booth No: 80Q19, welcome to visit us.